Moonlake Immunotherapeutics Stock EBITDA
| MLTX Stock | USD 54.17 0.15 0.28% |
MoonLake Immunotherapeutics fundamentals help investors to digest information that contributes to MoonLake Immunotherapeuti's financial success or failures. It also enables traders to predict the movement of MoonLake Stock. The fundamental analysis module provides a way to measure MoonLake Immunotherapeuti's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to MoonLake Immunotherapeuti stock.
| Last Reported | Projected for Next Year | ||
| EBITDA | -54.1 M | -51.4 M |
MoonLake | EBITDA |
MoonLake Immunotherapeutics Company EBITDA Analysis
MoonLake Immunotherapeuti's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current MoonLake Immunotherapeuti EBITDA | (54.11 M) |
Most of MoonLake Immunotherapeuti's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, MoonLake Immunotherapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
MoonLake EBITDA Driver Correlations
Understanding the fundamental principles of building solid financial models for MoonLake Immunotherapeuti is extremely important. It helps to project a fair market value of MoonLake Stock properly, considering its historical fundamentals such as EBITDA. Since MoonLake Immunotherapeuti's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of MoonLake Immunotherapeuti's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of MoonLake Immunotherapeuti's interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
MoonLake Ebitda
According to the company disclosure, MoonLake Immunotherapeutics reported earnings before interest,tax, depreciation and amortization of (54.11 Million). This is 106.17% lower than that of the Biotechnology sector and 154.03% lower than that of the Health Care industry. The ebitda for all United States stocks is 101.39% higher than that of the company.
MoonLake EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses MoonLake Immunotherapeuti's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of MoonLake Immunotherapeuti could also be used in its relative valuation, which is a method of valuing MoonLake Immunotherapeuti by comparing valuation metrics of similar companies.MoonLake Immunotherapeuti is currently under evaluation in ebitda category among its peers.
MoonLake Immunotherapeuti ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, MoonLake Immunotherapeuti's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to MoonLake Immunotherapeuti's managers, analysts, and investors.Environmental | Governance | Social |
MoonLake Immunotherapeuti Institutional Holders
Institutional Holdings refers to the ownership stake in MoonLake Immunotherapeuti that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of MoonLake Immunotherapeuti's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing MoonLake Immunotherapeuti's value.| Shares | Federated Hermes Inc | 2024-09-30 | 1.1 M | Marshall Wace Asset Management Ltd | 2024-06-30 | 1.1 M | Alliancebernstein L.p. | 2024-06-30 | 1 M | Paradigm Biocapital Advisors Lp | 2024-09-30 | 931.5 K | Polar Capital Holdings Plc | 2024-06-30 | 678.2 K | Fred Alger Management, Llc | 2024-09-30 | 666.6 K | Hood River Capital Management Llc | 2024-09-30 | 646.7 K | Nuveen Asset Management, Llc | 2024-06-30 | 521.7 K | Camber Capital Management Llc | 2024-09-30 | 441 K | Bvf Inc | 2024-09-30 | 21.8 M | Cormorant Asset Management, Llc | 2024-09-30 | 8.5 M |
MoonLake Fundamentals
| Return On Equity | -0.17 | ||||
| Return On Asset | -0.13 | ||||
| Current Valuation | 2.94 B | ||||
| Shares Outstanding | 63.06 M | ||||
| Shares Owned By Insiders | 15.22 % | ||||
| Shares Owned By Institutions | 98.14 % | ||||
| Number Of Shares Shorted | 8.06 M | ||||
| Price To Book | 7.02 X | ||||
| EBITDA | (54.11 M) | ||||
| Net Income | (44.08 M) | ||||
| Cash And Equivalents | 92.71 M | ||||
| Cash Per Share | 2.51 X | ||||
| Total Debt | 3.7 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 25.51 X | ||||
| Book Value Per Share | 7.74 X | ||||
| Cash Flow From Operations | (42.78 M) | ||||
| Short Ratio | 21.44 X | ||||
| Earnings Per Share | (1.27) X | ||||
| Target Price | 73.92 | ||||
| Number Of Employees | 50 | ||||
| Beta | 1.28 | ||||
| Market Capitalization | 3.43 B | ||||
| Total Asset | 526.54 M | ||||
| Retained Earnings | (116.66 M) | ||||
| Working Capital | 504.2 M | ||||
| Net Asset | 526.54 M |
About MoonLake Immunotherapeuti Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze MoonLake Immunotherapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of MoonLake Immunotherapeuti using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of MoonLake Immunotherapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for MoonLake Stock Analysis
When running MoonLake Immunotherapeuti's price analysis, check to measure MoonLake Immunotherapeuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MoonLake Immunotherapeuti is operating at the current time. Most of MoonLake Immunotherapeuti's value examination focuses on studying past and present price action to predict the probability of MoonLake Immunotherapeuti's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MoonLake Immunotherapeuti's price. Additionally, you may evaluate how the addition of MoonLake Immunotherapeuti to your portfolios can decrease your overall portfolio volatility.